NR1H4 and type 2 diabetes mellitus: Thus, FXR is today recognized as a potential target for novel pharmacotherapies addressing bile acid, lipid, and carbohydrate dysregulation, such as cholestasis, liver fibrosis, steatohepatitis, diabetes (T2DM), as well as obesity, metabolic syndrome, and inflammatory bowel disease [6,8,9].